Bruce Cohen

2 months ago | digitalcommons.library.tmc.edu | Amel Karaa |Enrico Bertini |Valerio Carelli |Bruce Cohen

BACKGROUND: As previously published, the MMPOWER-3 clinical trial did not demonstrate a significant benefit of elamipretide treatment in a genotypically diverse population of adults with primary mitochondrial myopathy (PMM).

May 25, 2023 | medscape.com | Bruce Cohen

We are living in an era of increasing sensitivity to our diversity and the ways we interact, but also an era of growing resistance to change and accommodation. As clinicians, we hope to be among the sensitive and the progressive, open to improving our views and interactions. And as part of our respect for those we treat, we seek to speak clearly with them about our assessment of what is disrupting their lives and about their options. Using the right words is crucial in that work.

May 19, 2023 | mdedge.com | Bruce Cohen

We are living in an era of increasing sensitivity to our diversity and the ways we interact, but also an era of growing resistance to change and accommodation. As clinicians, we hope to be among the sensitive and the progressive, open to improving our views and interactions. And as part of our respect for those we treat, we seek to speak clearly with them about our assessment of what is disrupting their lives and about their options. Using the right words is crucial in that work.